Hypomethylating agents such as decitabine and azacitidine with or without the BCL-2 inhibitor venetoclax rarely lead to long-term disease control in myeloid neoplasms (41), thus the addition IRAK-4 inhibition may deepen and prolong responses in patients with myeloid malignancies. The gene discussed is BCL2; the disease is myeloid neoplasm.